2. Academic Validation
  3. Alternative splicing of BCL-X and implications for treating hematological malignancies

Alternative splicing of BCL-X and implications for treating hematological malignancies

  • Oncol Lett. 2021 Sep;22(3):670. doi: 10.3892/ol.2021.12931.
Wanling Chen 1,  Jinggang Li 2
Affiliations

Affiliations

  • 1 Department of Clinical Medicine, Xiamen Medical College, Xiamen, Fujian 361023, P.R. China.
  • 2 Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China.
PMID: 34345295 DOI: 10.3892/ol.2021.12931
Abstract

BCL-X is a member of the Bcl-2 Family. It regulates Apoptosis and plays a critical role in hematological malignancies. It is well-known that >90% of human genes undergo alternative splicing. A total of 10 distinct splicing transcripts of the BCL-X gene have been identified, including transcript variants 1-9 and ABALON. Different transcripts from the same gene have different functions. The present review discusses the progress in understanding the different alternative splicing transcripts of BCL-X, including their characteristics, functions and expression patterns. The potential use of BCL-X in targeted therapies for hematological malignancies is also discussed.

Keywords

BCL-X; alternative splicing; hematological malignancies.

Figures